Abstract Details

Title Feasibility and Acceptability of Smartphone Based Migraine Behavioral Therapy in the Neurology Clinic: A Single Arm Study

Topic Headache

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 13-002

Objective

To study the feasibility and acceptability of a smartphone application (app) based progressive muscle relaxation (PMR) intervention for the self-management of migraine in a neurology outpatient setting.

Background PMR is an under-utilized Level A evidence-based treatment for migraine prevention. RELAXaHEAD is a smartphone application (app) that provides an electronic diary, has PMR audio recordings, and offers back-end analytics to capture the amount of time spent playing the PMR audio recordings.

Design/Methods In this exploratory single arm pilot study, adults with migraine (ICHD-3 criteria, 4+ headache attacks/month) who owned a smartphone and had not used behavioral migraine therapy in the past year were asked to use the app for 3 months by completing the headache diary on a daily basis and performing PMR using the app for 22 minutes/day. Back-end analytics assessed adherence at 3 months, including the per participant frequency of daily diary entries, as well as number and duration of PMR audio plays.

Results Fifty-one patients enrolled in the study between July 7, 2017-April 12, 2018. Ninety-four percent were female. Mean age was 39 years+13. 32(sd). The majority (63%) had severe migraine disability at baseline based on the migraine disability assessment scale (MIDAS). PMR was played a mean 26 days+36(sd), with a mean per session duration of 11 minutes +7.1(sd). Forty seven percent (311/663) of uses were 1+ time/week and 35% (230/663) of uses were 2+ times/week. There was attrition by week; most users of the app/PMR used it in the first 6 weeks of the 90-day period.

Conclusions In a convenience sample of 51 mostly female patients with severe migraine disability, about 1 out of every 2 patients demonstrated uptake of the smartphone based PMR intervention based upon a brief, initial introduction to the app. Also, there appeared time limited acceptability of the intervention by 6 weeks.

Authors/Disclosures
Mia T. Minen, MD, FAAN (NYULMC Neurology) PRESENTER	The institution of Dr. Minen has received research support from NIH. Dr. Minen has received intellectual property interests from a discovery or technology relating to health care. Dr. Minen has received personal compensation in the range of $500-$4,999 for serving as a First Contact-Primary Care Advisory Board Member with American Headache Society . Dr. Minen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PCORI grant on migraine evidence based map for stakeholders with ECRI .
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Thomas Berk, MD (Neura Health)	Dr. Berk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Impex Neuropharma. Dr. Berk has received publishing royalties from a publication relating to health care. Dr. Berk has received publishing royalties from a publication relating to health care.
Sarah Jinich	No disclosure on file
Scott Powers, PhD (Cincinnati Children's Hospital)	Scott Powers, PhD has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Theranica. The institution of Scott Powers, PhD has received research support from NIH. The institution of Scott Powers, PhD has received research support from PCORI. The institution of Scott Powers, PhD has received research support from Cystic Fibrosis Foundation. Scott Powers, PhD has a non-compensated relationship as a Associate Editor with The Journal HEADACHE that is relevant to AAN interests or activities. Scott Powers, PhD has a non-compensated relationship as a Member Board of Directors with American Headache Society that is relevant to AAN interests or activities.
Elizabeth Seng, PhD (Yeshiva University, Albert Einstein College of Medicine)	Dr. Seng has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Dr. Seng has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Theranica. Dr. Seng has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. The institution of Dr. Seng has received research support from NCCIH. Dr. Seng has received research support from Cystic Fibrosis Foundation. The institution of Dr. Seng has received research support from American Heart Association.
	No disclosure on file
Richard B. Lipton, MD, FAAN (Albert Einstein College of Medicine)	Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clexio. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has or had stock in Biohaven.Dr. Lipton has or had stock in Manistee.Dr. Lipton has or had stock in Axon.Dr. Lipton has or had stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��